Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Exelon & HUGE GROWING UNMET NEED

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon May 28, 2021 1:01pm

140 Views

Post# 33286822

RE:RE:RE:Exelon & HUGE GROWING UNMET NEED

GoldenInvestor wrote: Interesting when one breaks down the numbers & assess conservatively.

at a population of 422.5 million, & Demetia affecting 5-8.5% (WHO), thinking all the people that can benefit from a GUD marketing team and strong distribution network.

incredible opportunity for the people of South America & incredible for Knight!($$$) RECURRING!

& this is just the first product across all our geographies!

That's the key ... just the first product.
Love to know if it opens the door to a bigger partnership with Novartis in the Americas (x-USA).
Future acquirer of GUD by a company like Novartis? Tell you in about 5-10 years. Hahaha!

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks